Drug Database
Back to search

Poland· PL-100501326

Rozlytrek

A entrectinib product containing entrectinibum, registered in Poland by Roche Registration GmbH. The same ATC class is registered in 14 of our 19 countries.

ATC L01EX14

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedRozlytrekATCL01EX14REGISTER NO.PL-100501326PACKS LISTED1CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about entrectinibumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Entrectinib is registered in 14 of 19 countries.

Countries holding a registration under ATC L01EX14 (entrectinib), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 8 of them publish a price we can compare per daily dose
Search entrectinib products by name

Entrectinib · ATC L01EX14

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of entrectinib costs, country by country.

Normalised to the WHO defined daily dose (0.6 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Entrectinib · price per daily dose (0.6 g)

USD · FX 28 Sept 2026

  • CH Switzerland$216.58
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Entrectinibum
Manufacturer
Roche Registration GmbH
Country
Poland (PL)
ATC code
L01EX14
ATC class
Entrectinib
Defined daily dose
0.6 g, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    07613326094818

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

570 interactions on record for entrectinib.

Graded by severity as the source publishes them — 151 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check entrectinib against other medicinesHow interaction checks work

Entrectinib · interactions on record

570 records

  • 151 severe
  • 405 moderate
  • 14 minor

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • DolasetronA04AA04severe
  • AprepitantA04AD12severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Entrectinib in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All entrectinib products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Rozlytrek
  • Liechtenstein · Rozlytrek
  • Norway · Rozlytrek

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/9f02438b-1342-48c8-a04b-24330b6f3527
GET /v1/drugs/9f02438b-1342-48c8-a04b-24330b6f3527?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Granulat powlekany, w saszetce",
  "source": "urpl",
  "strength": "50 mg",
  "packaging": "07613326094818 ¦ Rpz ¦ EU/1/20/1460/003 ¦ 157208\n42 sasz. \n¦ UR/Z/4c/199/26 - 07613326094818",
  "substance": "Entrectinibum 50 mg",
  "common_name": "Entrectinibum",
  "pl_product_id": "100501326",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about entrectinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console